Aardvark Therapeutics to Present at Upcoming Investor Conferences in November

About this update from Aardvark Therapeutics, Inc.

[{"type":"image","alt":"Aardvark Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Aardvark Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":63,"url":"https://media.zenfs.com/en/globenewswire.com/fe55bd926bdb60296161677c87a21101"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_2n1g9xWdfu1GQlbvtkO7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/fe55bd926bdb60296161677c87a21101","width":300,"height":63}},"lazy":false},{"type":"text","content":"SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that it will present at the following conferences during November:","length":357,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Stifel 2025 Healthcare Conference in New YorkPresentation: Tuesday, November 11 at 4:40 p.m. ET","length":96,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":96,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"TD Cowen Treatment Advancements in Obesity & Related Disorders Summit (virtual) Presentation: Monday, November 24 at 3:00 p.m. ET","length":134,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":134,"olType":false},{"type":"text","content":"Live webcasts of each presentation will be accessible on the company’s website, www.aardvarktherapeutics.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.","length":253,"tagName":"p"},{"type":"text","content":"About Aardvark Therapeutics, Inc.Aardvark is a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of PWS and metabolic diseases. Recognizing hunger (the discomfort from not having eaten recently) is a distinct neural signaling pathway separate from appetite (the reward-seeking, desirability of food), our programs explore therapeutic applications in hunger associated indications and potential complementary uses with anti-appetite therapies. Our lead compound, oral ARD-101, is i...

More updates from Aardvark Therapeutics, Inc.